No Data
No Data
Earnings Call: INmune Bio Q3 2024 Results Show Progress in Clinical Trials
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
Scotiabank Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $22
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript Summary
INmune Bio GAAP EPS of -$0.60 Misses by $0.10
INmune Bio | 10-Q: Q3 2024 Earnings Report
No Data
No Data